Piotr Milecki

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Karim Fizazi, Michael A. Carducci, Matthew R. Smith et al. · The Lancet · 2011 · 2K citations · Full text

Medicine, Oncology, Urology +17

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events

Mitchell R. Smith, Robert E. Coleman, Laurence Klotz et al. · Annals of Oncology · 2014 · 145 citations · Full text

Medicine, Oncology, Bone Metabolism +16

Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer

Karim Fizazi, Christophe Massard, Matthew R. Smith et al. · European Urology · 2014 · 143 citations

Medicine, Oncology, Urology +16

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer

Cora N. Sternberg, Andrew J. Armstrong, Siobhan Ng et al. · Journal of Clinical Oncology · 2016 · 101 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study.

Katarzyna Hojan, Eliza Kwiatkowska-Borowczyk, Ewa Leporowska et al. · PubMed · 2016 · 94 citations

Medicine, Oncology, Radiation Oncology +16